Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Some high-level indication/class mechanism statements are consistent with labeled use, but many claims (patent/generic availability, side effects, pregnancy counseling, and alternative-diuretic comparisons) are not supported by the provided FDA label excerpts and cannot be verified against them.
Category Scores
Accurate Statements
Torsemide is a prescription medication used to treat fluid retention (edema) caused by heart failure.
Section 1: DEMADEX is indicated for treatment of edema associated with congestive heart failure; effectiveness for edema associated with chronic renal failure.
Torsemide is a prescription medication used to treat fluid retention (edema) caused by kidney disease.
Section 1: DEMADEX is indicated for edema associated with renal disease and effective for edema associated with chronic renal failure.
Torsemide is a prescription medication used to treat fluid retention (edema) caused by liver disease.
Section 1: DEMADEX is indicated for treatment of edema associated with hepatic disease.
Torsemide is used to treat high blood pressure.
Section 1: DEMADEX is indicated for treatment of hypertension alone or in combination with other antihypertensive agents.
Torsemide is a loop diuretic.
Torsemide works by helping the body get rid of extra salt and water through urination.
Torsemide reduces fluid buildup.
Section 1: indication for treatment of edema.
Torsemide can lower blood pressure.
Section 1: indication for hypertension.
Unsupported Statements
The generic name for Torsemide is torsemide.
The provided label excerpts do not address generic-name/generic-substance naming.
Torsemide is a loop diuretic.
The provided label excerpts do not explicitly state 'loop diuretic' or similar classification.
Torsemide works by helping the body get rid of extra salt and water through urination.
Mechanism-of-action wording is not provided in the supplied excerpts.
The original patent for torsemide expired in 2008.
Patent and regulatory history are not addressed in the supplied label excerpts.
The patent expiration allowed generic versions of torsemide to become available.
The supplied label excerpts do not discuss patents or generic availability.
Several pharmaceutical companies manufacture generic torsemide.
The supplied label excerpts do not discuss manufacturers or generic market availability.
Common side effects of torsemide include dizziness.
Adverse reaction content is not included in the supplied label excerpts (only partial warnings are shown).
Common side effects of torsemide include lightheadedness.
Adverse reaction content is not included in the supplied label excerpts.
Common side effects of torsemide include headache.
Adverse reaction content is not included in the supplied label excerpts.
More serious side effects of torsemide are possible and may require medical attention.
No 'more serious side effects' or medical-attention guidance is provided in the supplied excerpts.
Other diuretics such as furosemide may be used as alternatives to torsemide.
The supplied label excerpts do not mention alternative diuretics by name or substitution guidance.
Other diuretics such as bumetanide may be used as alternatives to torsemide.
The supplied label excerpts do not mention alternative diuretics by name or substitution guidance.
Torsemide is a potent loop diuretic.
The supplied label excerpts do not support 'potent' or provide diuretic classification language.
Torsemide is similar to furosemide.
The supplied label excerpts do not state similarity comparisons among diuretics.
Torsemide is similar to bumetanide.
The supplied label excerpts do not state similarity comparisons among diuretics.
The primary patents for torsemide have expired.
Patent status is not addressed in the supplied label excerpts.
The expired patents enable the production of generic versions of torsemide.
The supplied label excerpts do not discuss patents/generic enablement.
Risks associated with torsemide include dehydration.
The supplied excerpts include volume/electrolyte depletion warning, but do not use the specific term 'dehydration' or map it directly to a risk claim.
Risks associated with torsemide include electrolyte imbalances such as low potassium levels.
The excerpts support monitoring for electrolyte imbalance and prevention of hypokalemia in cirrhosis, but do not broadly enumerate 'low potassium levels' as a risk statement in the way claimed.
Risks associated with torsemide include potential interactions with other medications.
Drug interactions section text is not included in the supplied excerpts.
It is important to discuss all health conditions and medications with a doctor before starting torsemide.
This kind of general counseling is not stated in the supplied label excerpts.
The use of torsemide during pregnancy should be discussed with a healthcare provider.
Pregnancy/lactation sections are not provided in the supplied label excerpts.
Its safety profile in pregnant individuals is a consideration during treatment decisions.
Pregnancy-specific safety language is not provided in the supplied label excerpts.
Contradictions
Important Omissions
Dosage and administration details (specific starting doses, titration increments, and single-dose upper limits) are not provided in the AI response, despite the label excerpts containing detailed dosing guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Indication statements are broadly aligned, but unsupported claims about side effects, pregnancy counseling, and generic/patent history could mislead or distract from label-specific safety information. Missing dosing details also reduces label alignment for safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts (notably patents/generics, side effects, alternative drugs, and pregnancy discussion).
Suggested Improvement
Limit statements to what is supported by the provided label sections (Section 1 indications and Section 2 dosing guidance) and remove or qualify unsupported claims; include label-supported contraindications/warnings/adverse reactions only if their corresponding label text is provided.